Licensing agreement for CRISPR-Cas9 genome-editing patentsJuly 5th, 2024
FiledJuly 5th, 2024Bayer and ERS signed a patent license agreement whereby Bayer gains access to ERS' CRISPR-Cas9 genome-editing patents for certain cross-divisional applications in Bayer's core strategic areas.